MPLT Stock Analysis: MapLight Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.589m USD | 12M Return: 121.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.8M
Warnings
No concerns identified
Tailwinds
Seasonality 0.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MapLight Therapeutics, Inc. (NASDAQ: MPLT) is a clinical-stage biopharmaceutical company based in Redwood City, California, focused on developing therapeutics for debilitating central nervous system (CNS) disorders. The company was incorporated in 2018, originally as Alvarado Therapeutics, before adopting its current name in August 2019, and completed its initial public offering in October 2025.
The companys pipeline includes several drug candidates targeting CNS conditions: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist aimed at schizophrenia and Alzheimers disease psychosis; ML-004 for social communication deficits and irritability in autism spectrum disorder; ML-021 for motor deficits in Parkinsons disease; ML-055 for neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 (GPR52) positive allosteric modulator for hyperactivity, impulsivity, and agitation-related disorders.
As a clinical-stage biotech, MapLight has no products approved for commercial sale and its value is tied to the development progress of its pipeline candidates. The companys platform approach involves identifying neural circuits causally linked to specific diseases and then targeting those circuits for therapeutic modulation, which aligns with the broader industry focus in CNS drug development on circuit-based neuroscience to address historically difficult-to-treat neurological and psychiatric conditions.
- ML-007C-MA schizophrenia Phase 2 readout catalyst approaches
- Recent IPO cash runway funds CNS pipeline expansion
- Competition intensifies in muscarinic agonist schizophrenia space
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA 37.14 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.39 > 3% & CFO -163.8m > Net Income -199.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.3m) vs 12m ago 9.29% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.75 (Total Current Assets 327.2m - Total Current Liabilities 14.3m) / Total Assets 418.8m |
| B: -1.01 (Retained Earnings -421.2m / Total Assets 418.8m) |
| C: -0.75 (EBIT TTM -199.5m / Avg Total Assets 265.2m) |
| D: 21.09 (Book Value of Equity 399.8m / Total Liabilities 19.0m) |
| Altman-Z'' = 18.72 = AAA |
As of July 08, 2026, the stock is trading at USD 37.06 with a total of 588,335 shares traded. Over the past week, the price has changed by +8.05%, over one month by +25.80%, over three months by +53.52% and over the past year by +121.25%.
Current recommended Stop Loss: 33.90 (which is 8.5% or 1.3 ATR below the current price).
MapLight Therapeutics has no consensus analysts rating.
P/B = 4.2087
Revenue TTM = 0.0 USD
EBIT TTM = -199.5m USD
EBITDA TTM = -198.9m USD
Long Term Debt = 4.67m USD (estimated: total debt 5.59m - short term 920k)
Short Term Debt = 920k USD (from shortTermDebt, last quarter)
Debt = 5.59m USD (from shortLongTermDebtTotal, last quarter) (leases 5.59m already included)
Net Debt = -304.5m USD (calculated: Debt 5.59m - CCE 310.1m)
Enterprise Value = 1.28b USD (1.59b + Debt 5.59m - CCE 310.1m)
Interest Coverage Ratio = unknown (Ebit TTM -199.5m / Interest Expense TTM 0.0)
EV/FCF = -7.82x (Enterprise Value 1.28b / FCF TTM -164.3m)
FCF Yield = -12.79% (FCF TTM -164.3m / Enterprise Value 1.28b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 574k) / Revenue TTM)
Tobins Q-Ratio = 3.07 (Enterprise Value 1.28b / Total Assets 418.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.59m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -157.6m (EBIT -199.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.91 (Total Current Assets 327.2m / Total Current Liabilities 14.3m)
Debt / Equity = 0.01 (Debt 5.59m / totalStockholderEquity, last quarter 399.8m)
Debt / EBITDA = 1.53 (negative EBITDA) (Net Debt -304.5m / EBITDA -198.9m)
Debt / FCF = 1.85 (negative FCF - burning cash) (Net Debt -304.5m / FCF TTM -164.3m)
Total Stockholder Equity = 288.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -75.23% (Net Income -199.5m / Total Assets 418.8m)
RoE = -69.06% (Net Income TTM -199.5m / Total Stockholder Equity 288.9m)
RoCE = -67.96% (EBIT -199.5m / Capital Employed (Equity 288.9m + L.T.Debt 4.67m))
RoIC = -38.87% (negative operating profit) (NOPAT -157.6m / Invested Capital 405.4m)
WACC = 11.35% (E(1.59b)/V(1.59b) * Re(11.39%) + D(5.59m)/V(1.59b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 61.46 | Cagr: 4.03%
[DCF] Fair Price = unknown (Cash Flow -164.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.41 | Chg30d=-6.79% | Revisions=+0% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-1.25 | Chg30d=-2.94% | Revisions=+0% | Analysts=6
EPS current Year (2026-12-31): EPS=-5.14 | Chg30d=-4.28% | Revisions=+0% | GrowthEPS=+72.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-4.35 | Chg30d=+2.93% | Revisions=+0% | GrowthEPS=+15.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +0% (up=4, down=4)